Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Altin et al. [30] 2013 CR 1/2 PV 0/1 32 100% (1/1)
100% (2/2) 		NR Mean: 0.9 NR NR
Larrazabal-Moron et al. [49] 2009 CR 1/2 RDEB 0/1 12 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		NR 0% (0/1)
0% (0/2) 		100% (1/1)
100% (2/2)b
Lee et al. [50] 2007 CR 1/8 RDEB 1/0 17 100% (1/1)
100% (8/8) 		0% (0/1)
50% (1/2) 		NR 0% (0/1)
0% (0/8) 		NR
Muller et al. [54] 2010 CR 1/10 RDEB 1/0 36 100% (1/1)
100% (10/10) 		0% (0/1)
66.7% (2/3) 		0 0% (0/1)
0% (0/10) 		NR
Oliveira et al. [56] 2010 CR 1/2 RDEB 0/1 24 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 0% (0/1)
0% (0/2) 		NR
Alikhasi et al. [63] 2017 CR 1/8 RDEB 1/0 18 100% (1/1)
100% (8/8) 		NR NR NR NR
Letelier et al. [64] 2016 CR 1/6 RDEB 0/1 30 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		NR 0% (0/1)
0% (0/6) 		NR
Peñarrocha-Oltra et al. [72] 2020 RS 13/80 RDEB 4/9 Mean: 92 NR
97.5% (78/80)
Early loss: 1
Late loss: 1 		100% (13/13)
100% (20/20) 		Mean: 1.65 NR NR
Agustín-Panadero et al. [77] 2019 CS 4/31 RDEB 1/3 48 100% (4/4)
100% (31/31) 		100% (4/4)
100% (8/8) 		NR NR NR
Overall
BDs - CR: 7
CS: 1
RS: 1 		24/149 - Ratio: 1/2 Mean: 64.9 100% (11/11)
98.7% (147/149)
Of these: 50% (1/2) early loss 		90.9% (20/22)
94.4% (34/36) 		Mean: 1.42 0% (0/5)
0% (0/28) 		100% (1/1)
100% (2/2)b
BDs
+concomitant ADs 		- Irr. None - Irr. Irr. Irr. Irr. Irr. Irr. Irr.

a = weighted mean or median; b = criteria by Albrektsson et al. [119].
ADs = autoimmune diseases; CR = case report; CS = case series; Irr. = irrelevant; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; PV = pemphigus vulgaris; RDEB = recessive dystrophic epidermolysis bullosa; RS = retrospective study.